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Abstract
Background: Survival analysis is an important part of cancer studies. In addition to
the existing Cox proportional hazards model, deep learning models have recently been
proposed in survival prediction, which directly integrates multi-omics data of a large
number of genes using the fully connected dense deep neural network layers, which
are hard to interpret. On the other hand, cancer signaling pathways are important and
interpretable concepts that define the signaling cascades regulating cancer development and drug resistance. Thus, it is important to investigate potential associations
between patient survival and individual signaling pathways, which can help domain
experts to understand deep learning models making specific predictions.
Results: In this exploratory study, we proposed to investigate the relevance and
influence of a set of core cancer signaling pathways in the survival analysis of cancer
patients. Specifically, we built a simplified and partially biologically meaningful deep
neural network, DeepSigSurvNet, for survival prediction. In the model, the gene expression and copy number data of 1967 genes from 46 major signaling pathways were
integrated in the model. We applied the model to four types of cancer and investigated
the influence of the 46 signaling pathways in the cancers. Interestingly, the interpretable analysis identified the distinct patterns of these signaling pathways, which are
helpful in understanding the relevance of signaling pathways in terms of their application to the prediction of cancer patients’ survival time. These highly relevant signaling
pathways, when combined with other essential signaling pathways inhibitors, can be
novel targets for drug and drug combination prediction to improve cancer patients’
survival time.
Conclusion: The proposed DeepSigSurvNet model can facilitate the understanding of
the implications of signaling pathways on cancer patients’ survival by integrating multiomics data and clinical factors.
Keywords: Deep learning, Survival analysis, Signaling pathways, TCGA

Background
Survival analysis based on clinical factors (e.g., age, gender, race, stage) is crucial for
cancer prognosis. However, it is just as important to identify and understand essential
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original
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exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://
creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publi
cdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
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biomarkers given large-scale genomics data (e.g., gene expression and copy number variation). The cox proportional hazards model (Cox PH) model [1] is the classic model for
survival analysis. The Kaplan–Meier estimator curve [2], CoxPH model and logrank test
[3] are widely used to display and compare the survival probability over time of patients
in different groups or conditions. Recently, deep learning models have been developed
for survival analysis. Deep learning models have been used widely in image analysis [4,
5], medical informatics data analysis [6], and natural language process (NLP) [7], and
have shown exceptional performance over traditional machine learning models. Thus,
deep learning models developed for survival analysis are also promising, e.g., DeepSurv
[8], Cox-nnet [9], SCNN [10], and DeepHit [11].
Compared with the Cox PH model, the deep learning models showed improved prediction accuracy by flexibly integrating a large number of genomics features without
strong parametric assumptions. For example, the DeepSurv [8] model used the deep
neural network to integrate the biomarker genes and personal treatment information to
improve the survival time prediction. The DeepHit [11] model also used a deep neural
network, and jointly model different events, like different causes of death. In the liver
cancer subtyping and survival analysis [12], the auto-encoder model was first employed
to reduce the dimensions of the feature space given the large-number of genomics features (e.g., gene expression, miRNA, methylation). The important features (non-linear
combinations of raw genomics features) were identified using the Cox PH model [1] for
clustering analysis which identified sub-groups with distinct survival outcomes. Then,
the analysis of variance (ANOVA) based on the clustering results was applied to the raw
genomics features to further identify the important genes. However, the auto-encoder
model itself was not used to identify the important raw genomics features in a non-linear perspective. In the Cox-nnet model [9], RNA-seq data from The Cancer Genome
Atlas (TCGA) samples was used as the input in a deep neural network to predict the survival time. To identify the potentially associated signaling pathways of hidden nodes, the
Pearson’s correlation values between the expression of individual genes and the output
of the given hidden nodes were calculated to identify the most linearly correlated genes.
Then, gene set enrichment analysis (GSEA) [13] was employed to link the hidden nodes
with the enriched signaling pathways. Moreover, the Survival Convolutional Neural Networks (SCNN) [10] was developed to predict survival using histologic images of cancer
patients. Finally, heat map visualizations of the regions of interest (image patches) from
the SCNN model output were overlaid on the image to indicate the significant regions in
the images correlated with survival outcome.
Compared with existing models, we aimed to investigate the relevance or influence
of individual cancer signaling pathways (pathway level) to the survival time prediction
in cancer patients. In another word, instead of using multi-omics data of a large number of genes, a set of cancer signaling pathways were modeled using a simplified and
partially biological meaningful deep neural network architecture, which has not been
well investigated. In cancer studies, many dysfunctional signaling pathways that play
important roles in tumor development and drug response are identified. For example,
the analysis of ten signaling pathways using the TCGA cancer samples indicated that
many genetic biomarkers were included in the ten signaling pathways [14]. Such cancer signaling pathways and cancer hallmark networks have been used for prediction
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of cancer clinical phenotypes and cancer prognosis [15, 16]. In this study, we aimed to
investigate the relevance or influence of these signaling pathways within the context of
survival outcome prediction using a biologically meaningful and simplified deep learning model, DeepSigSurvNet. Specifically, only signaling pathways (46 pathways) were
collected from the KEGG [17] signaling database. The gene expression and copy number
data of 1967 genes from the 46 major signaling pathways are from four types of cancer:
breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), glioblastoma multiforme (GBM), and skin cutaneous melanoma (SKCM). The model was evaluated using
the c-index. Moreover, it is critical that domain experts can understand the mechanisms
of deep learning models making specific predictions. It is challenging because the complex network architectures. To interpret deep learning models’ prediction, a set of interpretation and explaining approaches have been proposed, e.g., the smmothgrad [18] and
Layer-Wise Relevance Propagation (LRP) approach [19], to identify the features that can
influence the model prediction results. Interestingly, the interpretable analysis using
the smoothgrad approach identified distinct probability density distribution patterns of
these signaling pathways, which can be helpful in understanding the relevance of the
signaling pathways in terms of their association with cancer patients’ survival. These
important signaling pathways can be novel targets for drug and drug combination prediction to improve cancer patients’ survival time. In the following sections, the materials
and methods, results and discussions are presented.

Methods
RNA‑seq and Copy number data of 4 types of cancer

From the UCSC Xena data server, the mean-normalized log2 scaled RSEM [20] values (per gene) across all TCGA cohorts (HiSeqV2_PANCAN dataset) and integer copy
number data (per gene) from GISTIC2 analysis were downloaded for four types of cancer: breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), glioblastoma
multiforme (GBM), and skin cutaneous melanoma (SKCM). The phenotype (clinical)
data (survival time, age, gender, stage, etc.) of the cancer samples are also available from
the Xena data server. Table 1 shows the number of cancer samples, dataset and URLs to
download these datasets. For the purposes of prediction, cancer patients with survival
times greater than 3000 days are not included.
The 46 major signaling pathways

KEGG (Kyoto Encyclopedia of Genes and Genomes) [17] is a database for the systematic understanding of gene functions. The KEGG signaling pathways provide knowledge
of signaling transduction and cellular processes. There are 303 pathways in the KEGG
database, and 45 of them are annotated as “signaling pathways”. Many of the signaling
pathways are important oncogenic signaling pathways [14], e.g., EGFR, WNT, Hippo,
Notch, PI3K-Akt, RAS, TGFβ, p53. The ‘cell cycle’ cellular process is also included. For
simplicity, the ‘cell cycle’ is also viewed as one ‘signaling’ pathway. In total, 46 signaling
pathways (45 signaling pathways + cell cycle) are selected (see Table 2). Among these 46
signaling pathways, there are 1967 genes with both gene expression and copy number
variation data. In summary, there are gene expression (TPM) and copy number variation
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Table 1 Number of samples, dataset_id and URLs to download the gene expression
and copy number data from UCSC Xena data server
Cancer type

DataSet

URLs

BRCA
(n = 1057)

HiSeqV2_PANCAN

https://xenabrowser.net/datap
ages/?cohort=TCGA%20Breast%20
Cancer%20(BRCA)&removeHub=https
%3A%2F%2Fxena.treehouse.gi.ucsc.
edu%3A443

LUAD
(n = 500)

Gistic2_CopyNumber_Gistic2_all_thresholded.
by_genes
HiSeqV2_PANCAN
Gistic2_CopyNumber_Gistic2_all_thresholded.
by_genes

GBM
(n = 484)

HiSeqV2_PANCAN

SKCM
(n = 358)

HiSeqV2_PANCAN

Gistic2_CopyNumber_Gistic2_all_thresholded.
by_genes

Gistic2_CopyNumber_Gistic2_all_thresholded.
by_genes

https://xenabrowser.net/datapages/?cohor
t=TCGA%20Lung%20Adenocarcinom
a%20(LUAD)&removeHub=https
%3A%2F%2Fxena.treehouse.gi.ucsc.
edu%3A443
https://xenabrowser.net/datap
ages/?cohort=TCGA%20Glioblas
toma%20(GBM)&removeHub=https
%3A%2F%2Fxena.treehouse.gi.ucsc.
edu%3A443
https://xenabrowser.net/datap
ages/?cohort=TCGA%20Melanoma
%20(SKCM)&removeHub=https
%3A%2F%2Fxena.treehouse.gi.ucsc.
edu%3A443

Table 2 The 46 signaling pathways used for analysis
MAPK

FoxO

TGF-beta

T cell receptor

Adipocytokine

ErbB

Sphingolipid

VEGF

B cell receptor

Oxytocin

Ras

Phospholipase D

Apelin

Fc epsilon RI

Glucagon

Rap1

p53

Hippo

TNF

Relaxin

Calcium

mTOR

Toll-like receptor

Neurotrophin

AGE-RAGE
Cell cycle

cGMP-PKG

PI3K-Akt

NOD-like receptor

Insulin

cAMP

AMPK

RIG-I-like receptor

GnRH

Chemokine

Wnt

C-type lectin receptor

Estrogen

NF-kappa B

Notch

JAK-STAT

Prolactin

HIF-1

Hedgehog

IL-17

Thyroid hormone

data of 1967 genes in 46 signaling pathways of 45 cancer cell lines, which was used as the
input for the deep learning model.
Model Architecture of DeepSigSurvNet

Figure 1 shows the schematic architecture of the proposed DeepSigSurvNet model. In
the ‘input layer’, there were two input features, i.e., normalized gene expression across
TCGA samples and integer copy number variation, for each gene. Genes that have
zero expression among training dataset will be excluded from input. In the model,
gene expression and copy number variation information were first linked to individual genes to compute gene state respectively for each gene. Then, the genes’ state
were connected to the 46 signaling pathways only if a gene was included in a signaling pathway (not a full connection layer). The gene connection matrix and pathway
connection matrix were used to design the connections. The output of the 46 signaling pathways was used as the input for the convolution and inception [21] layers
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Fig. 1 Schematic architecture of the DeepSigSurvNet model

(see Fig. 1). The inception [21] module used multiple kernel filter sizes in each layer,
instead of stacking more layers sequentially. It can capture informative features via
the dimension reduction and reduce the vanishing gradient problem. The activation
functions for the dense and convolution layers are the ReLU activation function.
The last dense layer uses a linear activation function. To better model and predict
the survival time of cancer patients, three clinical factors (age, gender and stage)
and the vital status were concatenated with the genomics data. To reduce overfitting
effects, the dropout layer and L2 weight decay were added in each inception module
and the dense layer. For the training parameters, the batch size was 32 and the optimizer was “Adadelta”. The loss function is mean square error between the real survival time and predicted survival time. We divided the cancer samples in each type
of cancer into training data (80%) and test data (20%). For the four cancer types, we
used the same model architecture with a different dropout rate, regularization value,
and epoch. After each epoch, we will evaluate the performance of model, the model
parameter with the best test c-index will be recorded. To investigate the relevance of
individual signaling pathways in survival time prediction, we employed the smoothgrad approach, which is available in the “iNNvestigate” package [22]. Specifically,
noise signals or perturbations would be added to individual signaling pathways, and
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corresponding changes on the model prediction accuracy will be calculated. The gradient of the prediction accuracy changes for each individual signaling pathways (features) can be calculated and smoothed to indicate their influence to the survival time
prediction. For the noise scale, we adjust it based on the input. To be more specific,
noisescale = (max (input) − min(input)) ∗ 0.1.Then the distributions of the relevance
scores of all 46 signaling pathways for each type of cancer were estimated using kernel
density estimation based on the relevance scores of all samples and were obtained in
order to investigate and understand the relevance of individual signaling pathways to
the patients’ survival.

Results
Model performance evaluation

To evaluate the performance of the proposed model, the concordance index (c-index)

yi > 
yj yi > yj be the
metric was used. The c-index is defined as follows. Let yi and 
 
yi > yj yi yj ), where
true and predicted survival time. The concordance is defined as P(
i and j are two randomly selected samples. The c-index indicates the probability that
the prediction and the real survival time are relatively consistent or concordant, i.e.,
yi > yj , and yi > yj , or yi < yj , and yi < yj . Let C, D, T represent the numbers for the
concordant, discordant, and equal survival times, then the c-index is defined as:

c−index =

C + 12 T
.
C +D+T

We compared the proposed model with the random forest model, which is available
as RandomForestRegression in the scikit-learn package. We trained the random forest model using the same training and test dataset settings for the four types of cancer.
The “n_estimator” and “max_depth” parameters were fine-tuned to find the best performance of the random forest models. For the DeepSigSurvNet model, we used the same
architecture for all four types of cancer, but different dropout rates, regularization values
and epoch numbers for each cancer type. Tables 3 and 4 show the comparison results.
As shown, the random forest model has higher c-index values in the training datasets.
However, it has much lower c-index values on the test datasets compared with the proposed DeepSignSurvNet model, which indicates that the proposed deep learning model
is robust.

Table 3 C-index values of random forest model in four types of cancer
Data set

n_estimator

Max_depth

c-index

Training-GBM

30

5

0.6550

Test-GBM

30

5

0.5598

Training-BRCA

40

7

0.7849

Test-BRCA

40

7

0.5946

Training-LUAD

30

6

0.7433

Test-LUAD

30

6

0.5593

Training-SKCM

60

9

0.9419

Test-SKCM

60

9

0.5112
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Table 4 C-index values of DeepSigSurvNet in four types of cancer
Data set

Epoch number

c-index

Training-GBM

35

0.6808

Test-GBM

35

0.6274

Training-BRCA

35

0.7930

Test-BRCA

35

0.6013

Training-LUAD

30

0.8263

Test-LUAD

30

0.7438

Training-SKCM

20

0.8103

Test-SKCM

20

0.7627

Table 5 Average c-index values of the proposed model and random forest model using
different amount of training data. The mean c-index was obtained by randomly selecting
the training and test dataset 50 times
Ratio of training
data (%)

Proposed model

Random forest model

Mean c_index
on training data

Mean c_index
on test data

Mean c_index
on training data

Mean c_index
on test data

50

0.6672

0.5869

0.7202

0.5383

60

0.6630

0.6033

0.7034

0.5404

70

0.6745

0.6029

0.6982

0.5450

80

0.6568

0.6085

0.6936

0.5493

90

0.6636

0.6392

0.6929

0.5612

50

0.7959

0.6961

0.7975

0.5178

60

0.7576

0.6680

0.7879

0.5237

70

0.7209

0.6950

0.7751

0.5277

80

0.7685

0.6717

0.7653

0.5255

90

0.7246

0.6643

0.7541

0.5208

50

0.6235

0.5435

0.8356

0.5217

60

0.6723

0.5768

0.8298

0.5262

70

0.6942

0.5627

0.8222

0.5154

80

0.7038

0.5835

0.8075

0.5026

90

0.7076

0.6157

0.8069

0.5036

50

0.7043

0.5857

0.8486

0.5641

60

0.7345

0.6708

0.8294

0.5702

70

0.6954

0.6363

0.8187

0.5704

80

0.7560

0.7249

0.8088

0.5809

90

0.7394

0.7419

0.8020

0.5822

GBM

SKCM

BRCA

LUAD

Considering the heterogeneity in TCGA dataset, multiple sampling at different ratios
were also performed for evaluation of robustness. Specifically, we have tested different
ratios of training data varying from 50, 60, 70, 80 and 90%, and repeated 50 times. The
epoch time was set to 25, and the average c-index value of the 50 testing was used. The
results are shown in Table 5. As seen, larger training dataset and small testing data have
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relatively better c-index values in the testing data. Overall, the proposed model outperformed the random forest on the testing data, though random forest model had better
performance on the training data.
To further test the influence of the number of pathways, the model was tested using
the 10, 20, 30 and 40 signaling pathways. Specifically, a number of signaling pathways,
e.g., 10 signaling pathways, were randomly selected for 50 times, using the 80% of
the data as training and 20% of the data as the test data. The average c-index values were listed in Table 6. As can be seen, more signaling pathways achieved better
c-index values in the training data and testing in general. The proposed model had
better performance than the random forest model on the testing dataset. The results
indicated that a small set of cancer signaling pathways are strongly informative for the
cancer survival time prediction. It might be because that many of the cancer signaling
pathways are overlapping and interact with each other. The random forest model had
much better performance on the training data. However, it had poor performance on
the testing data, which might be caused by the overfitting.

Table 6 Average c-index values of the proposed model and random forest model
using different numbers of randomly selected signaling pathways. The mean c-index
was obtained by randomly selecting the training (80% of the dataset) and test (20%
of dataset) data for 50 times
# of pathway

Proposed model

Random forest model

Mean c_index
on training data

Mean c_index
on test data

Mean c_index
on training data

Mean c_index
on test data

10

0.6428

0.6115

0.6832

0.5182

20

0.6442

0.6129

0.672

0.5159

30

0.6247

0.5975

0.6617

0.5314

40

0.6300

0.6196

0.6602

0.5418

10

0.6948

0.6626

0.7684

0.4943

20

0.7226

0.6702

0.7701

0.4434

30

0.7197

0.6614

0.772

0.4336

40

0.7629

0.6772

0.7739

0.4265

10

0.4397

0.3713

0.7859

0.5294

20

0.6051

0.4577

0.8029

0.5225

30

0.6661

0.5622

0.81

0.5282

40

0.6497

0.5506

0.8093

0.5139

10

0.7349

0.7050

0.8158

0.5195

20

0.7226

0.7131

0.8162

0.5349

30

0.7347

0.7171

0.8101

0.5551

40

0.7119

0.7226

0.8091

0.5669

GBM

SKCM

BRCA

LUAD

Feng et al. BMC Bioinformatics

(2021) 22:47

Relevance of individual signaling pathways in the four types of cancer

As discussed, it is interesting to investigate and understand how the individual signaling pathways contribute to the cancer patients’ survival prediction. After training
the deep learning models, we employed the ‘iNNvestigate’ package to calculate the
relevance scores of the individual signaling pathways on individual cancer patients in
each of the four types of cancer. Figures 2 and 3 show the probability density distributions of 46 signaling pathways in the four types of cancer.
Specifically, the BRCA, mTOR, Hedgehog, PI3K-Akt, TGF-beta, AMPK, VEGF, Apelin, Adipocytokine and Oxytocin signaling pathways have the strongest relevance scores.
P53, Wnt, Notch, NF-Kaapa B, FoxO, cGMP-PKG, cAMP, Chemokine, Sphingolipid,
Relaxin, and Thyroid hormone signaling pathways have relatively high relevance scores.
Surprisingly, the MAPK, ErbB, Ras, Rap1, and JAK-STAT signaling pathways as well as
the cell cycle are not well associated with patients’ survival outcome, even though it is

Fig. 2 Density distribution of the relevance scores of the 46 signaling pathways on BRCA (top) and LUAD
(bottom) cancers
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Fig. 3 Density distribution of the relevance scores of the 46 signaling pathways on GBM (top) and SKCM
(bottom) cancers

well known that these signaling pathways play important roles in cancer development.
However, they can be separated in BRCA cancer samples and identified as the essential
signaling pathways for patients’ survival outcome prediction. For LUDA, the patterns
of density distribution are different from BRCA. More signaling pathways show high
but not very strong relevance scores. For example, the MAPK, Ras, Rap1, cGMP-PKG,
HIF-1, mTOR, PI3K-Akt, Wnt, Notch Hedgehog, C-type lectin receptor, GnRH, Neurotrophin, and Thyroid hormone signaling pathways have relatively high and consistent
relevance scores. On the other hand, the AMPK, Hippo and NOD-like signaling pathways have zero-mean values but with great variance. Thus, it is hard to evaluate their relative importance in cancer patients’ survival prediction analysis. For GBM, the Ras, p53,
mTOR, PI3K-Akt, Notch, Hippo, TNF, Estrogen, Thyroid hormone and Relaxin signaling pathways have relatively high relevance scores; the other signaling pathways are
not correlated with patients’ survival. For SKCM, the patterns are similar to the LUAD
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cancer samples. The Ras, Calcium, cGMP-PKG, NF-Kappa B, HIF-1, FoxO, Sphingolipid,
Phospholipase D, p53, mTOR, Wnt, Hedgehog, NOD-like receptor, Estrogen, Prolactin,
and Thyroid hormone signaling pathways have relatively high and consistent relevance
scores. Whereas, the MAPK, Rap1, PI3K-Akt, AMPK, and VEGF signaling pathways
have zero-mean values but with great variance.
In summary, the probability density distribution patterns of all 46 signaling pathways
vary significantly among the four types of cancer. For example, the p53 and mTOR signaling pathways are strongly relevant to patients’ survival outcomes in BRCA, GBM, and
SKCM cancer patients, but not in the LUDA cancer patients. The MAPK, RAS, Rap1,
and ErBB signaling pathways are known as the important signaling pathways in cancer, but they are not strongly correlated with cancer patients’ survival outcome in the
prediction models. This might be because all of these important signaling pathways are
always activated in cancer patients. Thus, they are important targets for cancer therapy,
but not informative in terms of the survival time prediction. Also, the cell cycle signaling does not play an important role in the survival time prediction. Moreover, a small
set of signaling pathways (e.g., T cell receptor, B cell receptor, Fc epsilon RI, TNF) do
not show important contributions to the survival of cancer patients across all four types
of cancer. Also, for each type of cancer, less than half of the signaling pathways have
strong effects on the survival prediction. Thus, drugs and drug combinations that can
inhibit these essential signaling pathways as well as the signaling pathways with strong
relevance scores for each type of cancer might be effective in improving cancer patients’
survival time and outcome.

Discussion
Survival prediction is important in cancer studies. Deep learning models that integrate
multi-omics data have been proposed for survival prediction and have outperformed the
classic Cox PH model. Signaling pathways are important in cancer research to understand the signaling cascades regulating cancer development and drug response. However, it is challenging to understand the contributions of individual genes considering
the non-linear combinations of a large number of genomic features, e.g., gene expression, copy number variation. Instead of using a large number of genomics features, in
this study, we proposed a relatively biologically meaningful and simplified deep learning
model, DeepSigSurvNet, for survival prediction. In the model, the gene expression and
copy number data of 1967 genes from 46 major signaling pathways were used. The deep
learning model analysis on four types of cancer can identify the distinct patterns of these
signaling pathways, which are helpful in understanding the relevance of the signaling
pathways in the context of survival analysis. These pathways can also be novel targets
for drug and drug combination prediction to improve cancer patients’ survival outcome.
There are some improvements to the proposed model that need to be further investigated. In addition to the 46 signaling pathways, other KEGG pathways, like metabolism
pathways, will be further evaluated. Moreover, Gene oncology [23] (GO) terms provide
alternative meaningful biological processes (BP) (gene sets). Moreover, cancer subtype
information is often related to different survival patterns. Identification and incorporation of the subtype information can be useful to improve the model. In addition, validation using independent datasets is necessary in order to evaluate the generalizability of
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the model. Other omics data such as protein, methylation, and genetic mutation can be
conveniently integrated into the model in addition to the copy number, gene expression
data. As aforementioned, the important genes within the important signaling pathways
can be used as potential gene signatures to discover drugs using the connectivity map
(CMAP) [24, 25]. In this study, the proposed model is partially biological meaningful
due to the use of signaling pathways. However, the detailed signaling structure information has not been modeled. The deep graph neural network (GNN) could be used to
better model the signaling structure, i.e., cascade connections. We will investigate these
possible directions in future work.

Conclusion
In this study, we proposed a biologically meaningful and simplified deep learning model,
DeepSigSurvNet, based on a set of signaling pathways to model cancer patients’ survival. Multi-omics data and clinical factors can be integrated into the model in a relatively meaningful manner compared with existing deep learning models, and the model
is robust for testing data. The interpretable analysis can help researchers understand the
effects of individual signaling pathways and identify new therapeutic drugs that target
the top correlated signaling pathways relevant to patient survival time and outcome.
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